Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

Bita Moghaddam, Barbara W. Adams

Research output: Contribution to journalArticle

867 Citations (Scopus)

Abstract

Glutamatergic abnormalities have been associated with several psychiatric disorders, including schizophrenia and addiction. Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model. An agonist of this group of receptors, at a dose that was without effects on spontaneous activity and corticolimbic dopamine neurotransmission, attenuated the disruptive effects of phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. This behavioral reversal occurred in spite of sustained dopamine hyperactivity. Thus, targeting this group of receptors may present a nondopaminergic therapeutic strategy for treatment of psychiatric disorders.

Original languageEnglish (US)
Pages (from-to)1349-1352
Number of pages4
JournalScience
Volume281
Issue number5381
StatePublished - Aug 28 1998
Externally publishedYes

Fingerprint

Excitatory Amino Acid Agonists
Phencyclidine
Metabotropic Glutamate Receptors
Psychiatry
Dopamine
Schizophrenia
Locomotion
Short-Term Memory
Synaptic Transmission
Glutamic Acid
Animal Models
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. / Moghaddam, Bita; Adams, Barbara W.

In: Science, Vol. 281, No. 5381, 28.08.1998, p. 1349-1352.

Research output: Contribution to journalArticle

@article{06b7a7ad10eb415c99f9b3ece7f40535,
title = "Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats",
abstract = "Glutamatergic abnormalities have been associated with several psychiatric disorders, including schizophrenia and addiction. Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model. An agonist of this group of receptors, at a dose that was without effects on spontaneous activity and corticolimbic dopamine neurotransmission, attenuated the disruptive effects of phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. This behavioral reversal occurred in spite of sustained dopamine hyperactivity. Thus, targeting this group of receptors may present a nondopaminergic therapeutic strategy for treatment of psychiatric disorders.",
author = "Bita Moghaddam and Adams, {Barbara W.}",
year = "1998",
month = "8",
day = "28",
language = "English (US)",
volume = "281",
pages = "1349--1352",
journal = "Science",
issn = "0036-8075",
publisher = "American Association for the Advancement of Science",
number = "5381",

}

TY - JOUR

T1 - Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

AU - Moghaddam, Bita

AU - Adams, Barbara W.

PY - 1998/8/28

Y1 - 1998/8/28

N2 - Glutamatergic abnormalities have been associated with several psychiatric disorders, including schizophrenia and addiction. Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model. An agonist of this group of receptors, at a dose that was without effects on spontaneous activity and corticolimbic dopamine neurotransmission, attenuated the disruptive effects of phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. This behavioral reversal occurred in spite of sustained dopamine hyperactivity. Thus, targeting this group of receptors may present a nondopaminergic therapeutic strategy for treatment of psychiatric disorders.

AB - Glutamatergic abnormalities have been associated with several psychiatric disorders, including schizophrenia and addiction. Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model. An agonist of this group of receptors, at a dose that was without effects on spontaneous activity and corticolimbic dopamine neurotransmission, attenuated the disruptive effects of phencyclidine on working memory, stereotypy, locomotion, and cortical glutamate efflux. This behavioral reversal occurred in spite of sustained dopamine hyperactivity. Thus, targeting this group of receptors may present a nondopaminergic therapeutic strategy for treatment of psychiatric disorders.

UR - http://www.scopus.com/inward/record.url?scp=0032575715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032575715&partnerID=8YFLogxK

M3 - Article

C2 - 9721099

AN - SCOPUS:0032575715

VL - 281

SP - 1349

EP - 1352

JO - Science

JF - Science

SN - 0036-8075

IS - 5381

ER -